Delayed cardiac relaxation in failing hearts has been attributed to reduced activity and/or expression of SERCA2a. While constitutive over-expression of SERCA2a has proven effective in preventing cardiac dysfunction, it is unclear if increasing SERCA2a expression in hearts with pre-existing hypertrophy will be therapeutic.
Introduction
Abnormal Ca 2+ handling contributes to the contractile dysfunction observed in heart failure. Both, contraction and relaxation are altered in cardiac myocytes from humans and animal models of heart failure (6, 7) . Contraction and relaxation in cardiac myocytes is regulated by intracellular calcium ([Ca 2+ ] I ). The major contribution to diastolic calcium lowering is made by the sarcoplasmic reticulum Ca 2+ ATPase (SERCA2a), which pumps cytosolic calcium into the lumen of the sarcoplasmic reticulum (SR). It was demonstrated that steady state levels of SERCA2a mRNA are reduced in human heart failure due to dilated cardiomyopathy (1, 13, 15, 22, 24, 27) and in animal models with ischemia or pressure overload-induced heart failure (3). Most functional studies indicate decreased SERCA2a activity during heart failure. However, a concomitant decrease in SERCA2a protein levels is controversial (1, 9, 10) . Previous efforts focused on increasing SERCA2a expression to alleviate contractile dysfunction in animal models of heart failure. They demonstrated that constitutive SERCA2a over-expression (i.e. elevated SERCA2a levels) prior to pressure overloadinduced heart failure, prevented pressure overload-induced contractile and calcium handling abnormalities in both mice (12) and rats (19) . Furthermore, cardiac-specific over-expression of a high Ca 2+ affinity mutant of SERCA2a attenuated development of pressure overload-induced cardiac hypertrophy (20).
These studies show that "prophylactic" SERCA2a over-expression in a transgenic model is able to preserve cardiac function and myocyte contractile performance during pressure overload-induced heart failure. It remains unclear whether diminished contractile function and abnormalities in Ca 2+ handling of cardiac myocytes can be restored by inducible expression of SERCA2a. While it has been reported that adenoviral gene transfer of SERCA2a improved left ventricular function in aortic-banded rats transitioning to heart failure (19) , no data is available regarding Ca 2+ handling or contractility at the individual cardiac myocyte level. The lack of information at the cellular level with adenoviral gene transfer in vivo is due to technical difficulties in achieving homogenous adenoviral infection. In addition, adenoviral administration can lead to an inflammatory process that can jeopardize the specific effect of up-regulated SERCA2a. This study tested the hypothesis that conditional over-expression of SERCA2a can restore normal cardiac function, Ca 2+ handling and contractility in cardiac myocytes with established pressure overload-induced cardiac dysfunction. For this purpose we developed an inducible double transgenic mouse model with cardiac-specific over-expression of SERCA2a upon administration of tetracycline (tet-on SERCA2a) or doxycycline. We demonstrate that, in vivo, inducible SERCA2a expression restores calcium-handling abnormalities and contractility of pressure-overloaded cardiac myocytes, and improves global contractile function.
Materials and Methods
Generation of Transgenic Mice. The generation of binary transgenic (BTG) mice is illustrated in fig. 1A . Transgenic mice expressing a codon-optimized reverse tetracycline transactivator driven by the cardiac specific alpha-myosin heavy chain promoter (MHC-rtTA) have been previously described (29) . SERCA2a transgene was created by cloning the tetracycline response element (Tet-RE)
upstream of a rat SERCA2a transgene described previously (11) , containing the first and second introns and a C-terminal FLAG tag. This construct was injected into fertilized mouse eggs to generate Tet-RE-SERCA2a lines. These two lines were crossed to generate binary transgenic mice (rTA-SERCA2a). To determine transgene integration, genomic DNA was extracted from tails of 3-wk-old mice and subjected to Southern blot analysis. Animals carrying both transgenes Eco RI and cloned into pBKS II-. The radiolabeled cRNA was generated off the linearized pBKS II-clone using T7 RNA polymerase. RT-PCR was performed using the one step RT-PCR kit (Novagen) and the protocol recommended by the manufacturer. The primer for SERCA2a-FLAG was the same described above for RNase analysis.
Echocardiography. Transthoracic echocardiography was performed as previously described (28) . antibody as an internal control to ensure equivalent protein loading and protein integrity. Signals on the films were digitized on a 350-dots per inch scanner and densities of the bands were evaluated by using NIH IMAGE.
Generation of Cardiac Hypertrophy and Heart Failure by Ascending Aortic
Constriction. Mice were anesthetized with intraperitoneal ketamine:xylazine.
(50:2.5 mg/Kg) intubated and ventilated with room air. Aortic constriction was performed via a left thoracotomy by placing a ligature (6-0 Ethalon) securely around the ascending aorta and a blunted 26-gauge needle and then removing the needle. After banding, the thoracic cavity was closed; the mice were extubated and placed in recovery cages vented with 100% oxygen until they were fully recovered from anesthesia.
Isolation of Adult Ventricular Cardiomyocytes. Ca 2+ tolerant adult cardiomyocytes
were isolated from ventricular tissue of mice by standard enzymatic digestion.
Briefly, isolated hearts were perfused using a Ca 
Cell shortening measurements (edge detection). This technique has been
described previously (11) . Contractile studies of myocytes were performed with a video edge motion detector (Crescent Electronics, Sandy, UT) interfaced to a standard CCTV video camera (Panasonic Corp., Tokyo, Japan), which was attached to a Nikon Diaphot microscope (Melville, NY). A 40x Zeiss phase two objective was used. Output from the edge detector was interfaced to the RCQC reference channel of the photon Technologies photometry system to record data.
Calibration was achieved by focusing the microscope on 26-mm micro-spheres Statistical analysis. Data are expressed as mean ± standard error. A Student's t test or ANOVA followed by a Student-Newman-Keuls test was used to make comparisons between groups. A value of P<0.05 was considered statistically significant. A minimum of three independent experiments was performed for all components of the study.
Results

Generation of SERCA2a inducible transgenic mice.
A rat SERCA2a cDNA with a C-terminal FLAG tag was cloned in front of the tetracycline response element to generate Tet-RE-SERCA2a transgenic mice (Fig 1A) . SERCA2a protein levels increased only by 45% (Fig. 3) , interestingly, Fig. 4A ). Posterior wall thickening was also increased after induction of SERCA2a transgene expression (Fig. 4B ).
Calcium transients in isolated WT versus BTG cardiac myocytes (+ DOX)
showed an accelerated calcium decline (t 1/2 for WT= 146±11 ms vs. BTG= 91±6 ms, P<0.05, n=20 cells per group, Fig. 5 ) and a higher systolic Ca 2+ peak (Indo-1 ratio for WT=0.80±0.016 vs BTG=0.86±0.020 P<0.005, n=20, not shown).
Additionally, SR calcium load was increased by 45% in BTG isolated myocytes compared with WT (not shown). No change in the time to peak calcium occurred with SERCA2a over-expression. As a control, transients were compared in WT mice +/-DOX and no differences were observed (Fig.5) .
Reversion of calcium handling abnormalities and impaired contractility in pressure overloaded mouse hearts by inducible SERCA2a transgene expression.
We tested the hypothesis that the abnormal calcium handling and contractile function of the pressure-overloaded heart can be rescued by inducible SERCA2a expression. Pressure overload was induced by ascending aortic constriction (AC)
in BTG mice (see material and methods). Three weeks after AC, cardiac function was evaluated by echocardiography to obtain baseline pressure overload functional data. Following baseline analysis, SERCA2a expression was either initiated with DOX administration (the treated group) or not initiated (the untreated group). After 7 days, a second echocardiography was then performed and mice were sacrificed for cardiac myocyte isolation. Non-banded BTG mice were used as controls. Results of this experiment are shown in figure 6 . AC mice presented 100% increase in heart weight/body weight ratio compared to nonbanded mice (Fig. 6A) . Untreated AC BTG mice showed decreased fractional shortening and Vcf compared to non-banded (control) BTG (Fig. 6B and 6C ). In treated mice both the decrease in fractional shortening and Vcf were significantly improved and returned to values observed in the control group after SERCA2a over-expression was induced by DOX administration (Fig. 6B, 6C ).
In a separate series of experiments we determined whether or not the beneficial effects of increased SERCA2a expression on cardiac function observed in vivo by echocardiography could also result in an improvement of calcium handling and contractile function at the level of the individual cardiac myocyte. SERCA2a over-expression in AC BTG mice improved fractional cell shortening (Fig. 7A,B) , rate of contraction (dL/dt), and rate of relaxation (-dL/dt) ( fig. 7A,B ). This effect of SERCA2a induction on improving cell contractility was consistent with an improvement in calcium transients. For instance, the rate of calcium decline returned to control values in cells from treated AC BTG mice (Fig. 8) , and SR calcium loading increased by 70 % (AC + DOX; 1.038±0.181 vs. AC; 0.612±0.063 indo-1 ratio, p<0.05, n=17 per group, not shown). However, the time to peak calcium remained prolonged in treated AC BTG isolated myocytes.
The effect of SERCA2a induction on PLN to SERCA2a ratio. The PLN to
SERCA2a ratio has been suggested as a key regulator of SERCA2a activity (16) .
As expected, cardiac myocytes of untreated AC BTG mice showed a statistically significant decrease of SERCA2a protein levels compared with non-banded control myocytes (AC; 11901±27 vs. control; 12482±105, arbitrary units, P<0.05, n=5 for each group, Fig. 9 ). An increase of SERCA2a expression in treated mice was confirmed by immuno-blotting. Myocytes from treated AC BTC have higher total SERCA2a levels relative to untreated AC BTG mice; however, endogenous SERCA2a was similar in both groups (Fig. 9) . PLN protein levels were increased and SERCA2a protein levels were decreased following AC. Therefore, banded mice had a higher PLN/SERCA2a ratio (Fig. 9) . Induction of SERCA2a in AC BTG mice returned the ratio to control values (Fig. 9) . Expression of SERCA2a was confirmed only in banded AC BTG mice treated with DOX (Fig 9) .
Discussion
In this manuscript we report for first time that conditional expression of a SERCA2a-FLAG
